Radiocontrast Nephropathy: Redox Degradation Catalyst and Nitric Oxide Donor

放射性对比肾病:氧化还原降解催化剂和一氧化氮供体

基本信息

  • 批准号:
    8449038
  • 负责人:
  • 金额:
    $ 24.51万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-05-01 至 2015-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): We are developing a novel small molecule cytoprotective drug (R-100) for the prevention of contrast- induced nephropathy (CIN) following IV radiocontrast media (CM) injection. R-100 is a novel cell- permeable redox-active agent formed from the covalent fusion of 2 chemical moieties: 1) an organic nitrovasodilator that donates nitric oxide, and 2) a pyrrolidine nitroxide that acts as a trifunctional degradation catalyst of reactive oxygen species. In rats subjected to renal ischemia/reperfusion injury (RIRI), IV administration of R-100 prior to reperfusion reduced the 6 h elevations in serum creatinine, serum NGAL, tissue myeloperoxidase, and histologic score by 75-90% (p<10-14) and restored the reduction of creatinine clearance from 90% to 50% (p<0.01). In a murine RIRI model, 24 h creatinine elevations were entirely eliminated by a single dose of R-100 prior to reperfusion (p<0.01). Aim #1: Establish the pharmacodynamic (PD) profile of R-100 in models of CIN in healthy and diabetic rodents under conditions of normal hydration and aggressive volume loading Rats will be subjected to dehydration, prostaglandin synthetase inhibition, and an IV challenge of CM. A sham injury group will be compared to treatment of CM-challenged healthy rats with 3 dose levels of IV R-100, N-acetyl-cysteine (NAC), or vehicle control initiated 10 min before CM administration and continued for 48 h. Rats will then be evaluated at 48 h for renal function (and parameters reflecting renal injury, including protein release into the blood (NGAL, KIM-1), pro-inflammatory transcription factor expression (cytoplasmic I¿B¿ degradation, nuclear p65 translocation), histologic damage, and nuclear damage and DNA repair (PARP activation and nitrosative stress as noted by poly(ADP-ribose) and 3-nitrotyrosine (3-NT) tissue immunoreactivity). In order to better model the patient population at greatest risk of CIN, the optimal dose of R-100 will then be further evaluated, using the same experimental approach and design as before, but in rats previously rendered diabetic 2 weeks earlier by injection of streptozotocin (STZ). Finally, we will investigate whether further benefit may be obtained in the diabetic setting by combining the administration of R-100 with aggressive volume resuscitation. Aim #2: Establish the pharmacokinetics (PK) of R-100 in a rodent model of CIN We will carry out PK studies in rodents exposed to the same conditions utilized to generate CIN as in Aim #1. A full PK profile will be generated, to define plasma half-life, clearance, and volume of distribution. The exposure to cumulative plasma concentrations of R-100 and the renal tissue concentration of R-100 will be correlated with the morphologic, immunologic, and functional endpoints detailed in Aim #1, in order to construct a PD profile relating drug exposure to effect. The proposed studies will provide a rational foundation for advanced commercial development of R-100, with the intent that this product will serve as first-line prophylaxis in high-risk diabeic patients undergoing CM injection.
描述(由申请人提供):我们正在开发一种新型小分子细胞保护药物(R-100),用于预防静脉注射放射性造影剂(CM)后造影剂肾病(CIN)。 R-100 是一种新型细胞渗透性氧化还原活性剂,由 2 个化学部分共价融合而成:1) 提供一氧化氮的有机硝基血管舒张剂,2) 吡咯烷氮氧化物,充当活性氧的三功能降解催化剂。在遭受肾缺血/再灌注损伤(RIRI)的大鼠中, 再灌注前静脉注射 R-100 可将 6 小时内血清肌酐、血清 NGAL、组织髓过氧化物酶和组织学评分的升高降低 75-90% (p<10-14),并将肌酐清除率的降低从 90% 恢复至 50% (p<0.01)。在小鼠 RIRI 模型中,再灌注前单剂量的 R-100 完全消除了 24 小时肌酐升高(p<0.01)。目标#1:在正常水合和剧烈容量负荷的条件下,在健康和糖尿病啮齿动物的 CIN 模型中建立 R-100 的药效学 (PD) 概况 大鼠将经历脱水、前列腺素合成酶抑制和 CM 的 IV 攻击。将假损伤组与用 3 个剂量水平的 IV R-100、N-乙酰半胱氨酸 (NAC) 或载体对照对 CM 攻击的健康大鼠进行比较,在 CM 给药前 10 分钟开始并持续 48 小时。然后在 48 小时评估大鼠的肾功能(以及反映肾损伤的参数,包括蛋白质释放到血液中(NGAL、KIM-1)、促炎转录因子表达(细胞质 I¿B 降解、核 p65 易位)、组织学损伤、核损伤和 DNA 修复(由聚(ADP-核糖)和 3-硝基酪氨酸 (3-NT) 组织免疫反应性)。为了更好地模拟 CIN 风险最大的患者群体,将使用与之前相同的实验方法和设计进一步评估 R-100 的最佳剂量,但在 2 周前通过注射链脲佐菌素 (STZ) 导致糖尿病的大鼠中。最后,我们将研究通过联合服用以下药物是否可以在糖尿病患者中获得进一步的益处: R-100 具有积极的容量复苏功能。目标#2:在 CIN 啮齿动物模型中建立 R-100 的药代动力学 (PK) 我们将在暴露于与目标#1 中用于产生 CIN 相同条件的啮齿动物中进行 PK 研究。将生成完整的 PK 曲线,以定义血浆半衰期、清除率和分布体积。 R-100 累积血浆浓度和肾组织的暴露 R-100 的浓度将与目标 #1 中详述的形态学、免疫学和功能终点相关联,以便构建与药物暴露与效果相关的 PD 概况。拟议的研究将为 R-100 的高级商业开发提供合理的基础,旨在使该产品成为接受 CM 注射的高危糖尿病患者的一线预防药物。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Zsuzsanna Kinga Zsengeller其他文献

Zsuzsanna Kinga Zsengeller的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Zsuzsanna Kinga Zsengeller', 18)}}的其他基金

Organophosphate intoxication: effect of PARS inhibition
有机磷中毒:PARS 抑制作用
  • 批准号:
    6738690
  • 财政年份:
    2004
  • 资助金额:
    $ 24.51万
  • 项目类别:
Novel xanthine oxidase inhibitor for arthritis
新型黄嘌呤氧化酶抑制剂治疗关节炎
  • 批准号:
    6825387
  • 财政年份:
    2004
  • 资助金额:
    $ 24.51万
  • 项目类别:

相似海外基金

抗酸化能を高めたN-acetylcysteineによる老視と白内障抑制機構の解明
阐明具有增强抗氧化能力的N-乙酰半胱氨酸抑制老花眼和白内障的机制
  • 批准号:
    23K15945
  • 财政年份:
    2023
  • 资助金额:
    $ 24.51万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Targeting the neurobiology of restricted and repetitive behaviors in children with autism using N-acetylcysteine
使用 N-乙酰半胱氨酸针对自闭症儿童限制性和重复性行为的神经生物学
  • 批准号:
    10758985
  • 财政年份:
    2023
  • 资助金额:
    $ 24.51万
  • 项目类别:
Targeting the neurobiology of restricted and repetitive behaviors in children with autism using N-acetylcysteine
使用 N-乙酰半胱氨酸针对自闭症儿童限制性和重复性行为的神经生物学
  • 批准号:
    10619173
  • 财政年份:
    2022
  • 资助金额:
    $ 24.51万
  • 项目类别:
High dose acetaminophen with n-acetylcysteine rescue as a novel STAT3 inhibitor with anti-cancer stem cell properties
高剂量对乙酰氨基酚与 n-乙酰半胱氨酸救援作为具有抗癌干细胞特性的新型 STAT3 抑制剂
  • 批准号:
    10517287
  • 财政年份:
    2021
  • 资助金额:
    $ 24.51万
  • 项目类别:
A randomised controlled trial of N-acetylcysteine for the treatment of alcohol use disorder
N-乙酰半胱氨酸治疗酒精使用障碍的随机对照试验
  • 批准号:
    nhmrc : 2001375
  • 财政年份:
    2021
  • 资助金额:
    $ 24.51万
  • 项目类别:
    Clinical Trials and Cohort Studies Grants
High dose acetaminophen with n-acetylcysteine rescue as a novel STAT3 inhibitor with anti-cancer stem cell properties
高剂量对乙酰氨基酚与 n-乙酰半胱氨酸救援作为具有抗癌干细胞特性的新型 STAT3 抑制剂
  • 批准号:
    10368472
  • 财政年份:
    2021
  • 资助金额:
    $ 24.51万
  • 项目类别:
N-acetylcysteineの骨治癒促進効果の検討
N-乙酰半胱氨酸促进骨愈合作用的考察
  • 批准号:
    20H01118
  • 财政年份:
    2020
  • 资助金额:
    $ 24.51万
  • 项目类别:
    Grant-in-Aid for Encouragement of Scientists
Targeting the neurobiology of restricted and repetitive behaviors in children with autism using N-acetylcysteine
使用 N-乙酰半胱氨酸针对自闭症儿童限制性和重复性行为的神经生物学
  • 批准号:
    10221760
  • 财政年份:
    2020
  • 资助金额:
    $ 24.51万
  • 项目类别:
SLE Treatment with N-acetylcysteine
N-乙酰半胱氨酸治疗 SLE
  • 批准号:
    10188441
  • 财政年份:
    2020
  • 资助金额:
    $ 24.51万
  • 项目类别:
SLE Treatment with N-acetylcysteine
N-乙酰半胱氨酸治疗 SLE
  • 批准号:
    10462621
  • 财政年份:
    2020
  • 资助金额:
    $ 24.51万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了